BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 36472155)

  • 1. Prescribing Patterns of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Retrospective Cohort Analysis.
    Reyes JL; Herzog CA; Yan H; Roetker NS; Wetmore JB
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221142220. PubMed ID: 36472155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation in Patients with Chronic Kidney Disease.
    Elenjickal EJ; Travlos CK; Marques P; Mavrakanas TA
    Am J Nephrol; 2024; 55(2):146-164. PubMed ID: 38035566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation.
    Wetmore JB; Roetker NS; Yan H; Reyes JL; Herzog CA
    Stroke; 2020 Aug; 51(8):2364-2373. PubMed ID: 32640949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries.
    Wheelock KM; Ross JS; Murugiah K; Lin Z; Krumholz HM; Khera R
    JAMA Netw Open; 2021 Dec; 4(12):e2137288. PubMed ID: 34870678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
    Jackevicius CA; Lu L; Ghaznavi Z; Warner AL
    Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007230. PubMed ID: 33541109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
    Cheung CL; Sing CW; Lau WCY; Li GHY; Lip GYH; Tan KCB; Cheung BMY; Chan EWY; Wong ICK
    Cardiovasc Diabetol; 2021 Mar; 20(1):71. PubMed ID: 33766030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021).
    Alkhameys S; Barrett R
    Curr Med Res Opin; 2022 Jul; 38(7):1081-1092. PubMed ID: 35582854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan.
    Chan YH; Yeh YH; Hsieh MY; Chang CY; Tu HT; Chang SH; See LC; Kuo CF; Kuo CT
    Int J Cardiol; 2018 Aug; 265():83-89. PubMed ID: 29885705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
    Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
    Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
    Amin A; Keshishian A; Hines DM; Dina O; Le H; Rosenblatt L; Liu X; Zhang Q; Vo L
    Curr Med Res Opin; 2022 Dec; 38(12):2131-2140. PubMed ID: 35993487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin.
    Wetmore JB; Yan H; Herzog CA; Weinhandl E; Reyes JL; Roetker NS
    Am J Kidney Dis; 2021 Aug; 78(2):180-189. PubMed ID: 33421454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.
    Aggarwal R; Ruff CT; Virdone S; Perreault S; Kakkar AK; Palazzolo MG; Dorais M; Kayani G; Singer DE; Secemsky E; Piccini J; Tahir UA; Shen C; Yeh RW
    Circulation; 2023 Sep; 148(12):936-946. PubMed ID: 37621213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latent Classes of Adherence to Oral Anticoagulation Therapy Among Patients With a New Diagnosis of Atrial Fibrillation.
    Chen N; Brooks MM; Hernandez I
    JAMA Netw Open; 2020 Feb; 3(2):e1921357. PubMed ID: 32074287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Direct Oral Anticoagulants in Thai Patients with Atrial Fibrillation: A Real-World Retrospective Cohort Study.
    Srikajornlarp S; Amnueypol M; Vathesatogkit P; Numthavaj P; Ungkanont A; Likittanasombat K; Pattanaprateep O; Angchaisuksiri P; Boonyawat K
    Clin Appl Thromb Hemost; 2022; 28():10760296221130058. PubMed ID: 36198021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.